#Clinical Trials Peru | Explore Tumblr Posts and Blogs

afeelgoodblog · 1 year

Text

The Best News of Last Week - June 13, 2023

1. U.S. judge blocks Florida ban on care for trans minors in narrow ruling, says ‘gender identity is real’

A federal judge temporarily blocked portions of a new Florida law that bans transgender minors from receiving puberty blockers, ruling Tuesday that the state has no rational basis for denying patients treatment.

Transgender medical treatment for minors is increasingly under attack in many states and has been subject to restrictions or outright bans. But it has been available in the United States for more than a decade and is endorsed by major medical associations.

2. Eagle Who Thought Rock Was an Egg Finally Gets to Be a Dad

A week after their introduction the cage where the little eaglet was put, was removed so the two could interact more closely. When they were given food, a whole fish for Murphy and bite-sized pieces for his young charge, rather than each eating their separate dish, Murphy took his portion and ripped it up to feed to the baby.

3. Little penguins to reclaim Tasmanian car park as city-based population thrives

Not far from the centre of Tasmania's fourth largest city, a colony of the world's smallest penguins has been thriving, and their habitat is about to expand into an existing car park.

The bright lights and loud noises of Burnie have not been a deterrent for hundreds of penguins who set up home on the foreshore in the north-west Tasmanian city.

4. Latest population survey yields good news for endangered vaquita porpoise

The resilient little vaquita marina appears determined to survive the illegal fishing that has brought it dangerously close to extinction, according to the latest population survey. Despite an estimated annual decline of 45% in 2018, the endangered porpoise appears to be holding steady over the last five years, according to a report published Wednesday by the International Union for Conservation of Nature.

5. 'Extinct' butterfly species reappears in UK

The species, previously described as extinct in Britain for nearly 100 years, has suddenly appeared in countryside on the edge of London. Small numbers of black-veined whites have been spotted flying in fields and hedgerows in south-east London. First listed as a British species during the reign of King Charles II, they officially became extinct in Britain in 1925.

This month they have mysteriously appeared among their favourite habitat: hawthorn and blackthorn trees on the edge of London, where I and other naturalists watched them flitting between hedgerows.

6. Colombian is a hero in Peru: he rescued 25 puppies that were about to die in a fire

During a structural fire that occurred in a residential area of Lima in Peru, a young Colombian became a hero. The Colombian, identified as Sebastián Arias, climbed onto the roof where the puppies were and threw them towards the community, that was waiting for them with sheets and mattresses. "I love them, dogs fascinate me," said the young man.

7. World-first trial for pediatric brain cancer

Researchers in Australia are conducting a world-first clinical trial for children diagnosed with ependymoma, a rare and devastating brain cancer. The trial aims to test a new drug called Deflexifol, which combines chemotherapy drugs 5-FU and leucovorin, offering potentially less toxic and more effective treatment compared to current options.

Ependymoma is the third most common brain tumor in children, and current treatments often lead to relapses, with a high fatality rate for those affected. The trial, led by researcher David Ziegler at the Kids Cancer Centre, has received support from the Kids with Cancer Foundation and the Cancer Institute NSW. The goal is to find a cure for every child diagnosed with ependymoma.

----

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation:

BUY ME A COFFEE ❤️

Also don’t forget to reblog.

SUBCRIBE HERE for more good news in your inbox

#best news of last week

604 notes · View notes

naturalrights-retard · 7 months

Text

by Sonia Elijah

Two years ago, I wrote an investigative report for Trial Site News on how an essential, cheap and provenly effective drug for treating COVID-19, suddenly became blacklisted by global health authorities, whilst coming under fire from a smear campaign led by the FDA and championed by the mainstream media. My report focused on a particular group calling themselves the ‘fraud detectives’ and how they targeted clinical trials for ivermectin with the sole purpose to expose them as ‘fraudulent.’ It can be read below.

From its humble beginnings, derived from an isolated bacterial culture from Japanese soil 46 years ago, to a Nobel prize-winning and anti-parasitic drug, included in the World Health Organisation’s essential list of medicines--ivermectin is one of modern science’s major success stories.

However, from the onset of the pandemic, this cheap generic drug, which for decades has safely cured people of river blindness in 33 countries, with more than 3.7 billion doses administered, has rapidly become public enemy #1 for the fact-checkers when the drug was repurposed as an early treatment and prophylaxis (preventative) for Covid-19.

To date, there have been 31 RCTs (Randomized Controlled Trials), 64 controlled studies, and 7 meta-analyses of the RCTs done on ivermectin. All of them found that ivermectin significantly reduced mortality and hospitalization rates as well as the risk of contracting Covid-19. In Mexico City, over 50,000 patients were treated early with ivermectin, resulting in up to a 75% reduction in hospitalization rates, compared to over 70,000 who were not treated. In Peru, a mass distribution program of ivermectin, led to a 74% drop in excess deaths within a month. Similar success stories were found in Las Pampas and La Misiones regions in Argentina.

16 notes · View notes

cassandralexxx · 4 months

Text

idk why but the Sony marvel movies always get me with the random medical thing they mention 💀.

Like online other people made fun of Morbius when he talks about his illness the whole “until they find it, the only way to stay alive is an oil change three times a day.” Which I understand how dumb it is.

HOWEVER, I watched morbius during one of the weeks when I was getting my infusions. So like I understood in a sense. I could relate to having a medical condition that weakened you. He had his infusions three times a day and I had mine a week straight every month where I had a PIV just stuck in my hand. That euphoria at strength at being normal reminded me of myself with my own medications that made such a great difference within my own life.

seeing a character with a physical disability in that way that needed infusions felt like a sucker punch bc that was me when I was watching that movie. Sat in that theatre with a PIV in my hand after hours hooked to a machine and it felt like connection.

Watching Madame Web also similar thing. Myasenthia Gravis. That felt like such a slap in the face bc while I have another condition I’m currently in a clinical trial for a medication that is already FDA approved for MG. Like when discussing my condition I’ve read a lot of blogs and information of ppl with MG. my friend turned to me in the theatre to like laugh at the part where she finds out her mom went to Peru to find a cure for her MG and that wasn’t funny for me. That was reality that was a mom’s love for her kid. That’s a real medical condition that I find a lot of connection with my own.

like I always find the connection and I’m like 😟 bc I don’t expect it. I don’t expect for the shitty (but fun) movie to be applicable and relatable to my life but it is

#mylife #Myrambles #morbius 2022 #Madame web 2024 #I get they are dumb movies #I don’t disagree they are silly and poorly made poorly written #But I keep finding a connection in them and it is always so shocking idk

2 notes · View notes

dollsworks6374 · 6 days

Text

Semaglutide: Transforming Chronic Disease Treatment in Latin America

Introduction to Semaglutide Semaglutide is a game-changer in the medical field, particularly Peptide Xperts for the treatment of type 2 diabetes and obesity. This synthetic peptide mimics the natural GLP-1 hormone, providing a new and effective approach to managing these conditions. Its introduction has been met with great enthusiasm across the globe, including in Latin America, where its benefits are being increasingly recognized.

Mechanism of Action Semaglutide works by activating GLP-1 receptors, which enhances insulin secretion when blood sugar levels are high and suppresses glucagon release. This dual action helps maintain stable blood glucose levels. Additionally, Semaglutide slows gastric emptying and promotes a feeling of fullness, which aids in weight loss and improves overall metabolic health.

Clinical Applications and Benefits The primary use of Semaglutide is in the treatment of type 2 diabetes. Clinical studies have shown that it significantly lowers HbA1c levels, a key marker of long-term blood glucose control. Beyond its glucose-lowering effects, Semaglutide has been found to facilitate substantial weight loss, making it a valuable tool for managing obesity. The weight loss benefits extend to reducing cardiovascular risks, providing a comprehensive approach to health management.

Regulatory Approval and Availability in Latin America In countries like Colombia, Peru, Ecuador, Argentina, Venezuela, and Chile, Semaglutide has been approved by health authorities for the treatment of type 2 diabetes and obesity. These approvals come after rigorous evaluation processes that ensure the medication's safety and efficacy, enabling wider access for patients in need.

Healthcare Systems and Prescription Practices Healthcare systems in Latin America have integrated Semaglutide into their treatment protocols for diabetes and obesity. In nations such as Argentina and Chile, endocrinologists and primary care physicians are at the forefront of prescribing Semaglutide, ensuring that patients receive comprehensive and personalized care plans. These systems are designed to support patient adherence and maximize therapeutic outcomes.

Cost and Insurance Coverage The cost of Semaglutide varies across Latin America. In Argentina and Chile, public health insurance and private insurers often cover the majority of the treatment costs, making it more accessible to a broader population. In contrast, in Peru and Ecuador, patients may face higher out-of-pocket expenses. Efforts are ongoing to improve insurance coverage and reduce financial barriers to access in these regions.

Patient Education and Support Programs Effective management of diabetes and obesity with Semaglutide relies heavily on patient education. Countries like Colombia and Argentina have implemented robust patient support programs that offer educational resources, counseling, and regular follow-ups. These programs aim to enhance patient understanding of their treatment, promote adherence, and ultimately improve health outcomes.

Local Research and Clinical Trials Latin America is actively contributing to the global body of research on Semaglutide. Clinical trials conducted in countries such as Argentina and Chile are exploring various aspects of Semaglutide, including its long-term effects and potential new therapeutic applications. These studies are crucial for adapting treatment approaches to local populations and advancing medical knowledge.

Adverse Effects and Safety Profile Semaglutide is generally well-tolerated, but like all medications, it can cause side effects. Common adverse effects include nausea, vomiting, and gastrointestinal discomfort, especially at the start of treatment. These side effects are usually temporary and manageable. Healthcare providers in Latin America are well-equipped to monitor and address any issues, ensuring a favorable safety profile for patients.

Consultation and Specialist Care Specialist care is essential for patients considering Semaglutide therapy. Endocrinologists and diabetes specialists in Colombia, Peru, Ecuador, Argentina, Venezuela, and Chile are available to provide expert consultations and personalized treatment plans. These healthcare professionals are crucial in guiding patients through their treatment options and ensuring optimal outcomes.

Conclusion Semaglutide has revolutionized the management of type 2 diabetes and obesity, offering significant benefits in blood glucose control and weight reduction. Its regulatory approval and growing availability in Latin America mean that patients in countries such as Colombia, Peru, Ecuador, Argentina, Venezuela, and Chile can access this innovative therapy. With comprehensive education, supportive healthcare systems, and specialized care, Semaglutide can dramatically improve the quality of life for individuals managing these chronic conditions. For personalized consultation and further information, patients are encouraged to reach out to local healthcare providers and specialists.

0 notes

smukher2 · 17 days

Text

By #www.smukher2.com #www.smukher2.eu #www.smukher2.co.uk #www.smukher2.org #www.smukher2.net #smukher2 to #Everyone:

Just when I thought, there is some respite from the woke equity inclusion (DEI) crap, there are #StephenColbert "back to black" podcast episode and #TheGuardian science "is there systemic racism in medicine putting black people's lives at risk?" https://www.theguardian.com/science getting it started again. Here are reasons, why I think this is bullsh*t, let me explain once and for all, and as in keeping with FAIR principle anyone reading this is welcome to use knowledge shared here (this messgae will not be deleted).: 1) Planet Earth destruction is due to overpollution which in turn is due to human overpopulation mainly by black, brown, chinese, jews, and muslims. All people must be eliminated from South America and Africa, so that they can serve as "lungs of planet earth". Like Antarctice, in Africa and South America people will visit only for research and non-research people will travel there in restricted numbers not like how Mount Everest is being ruined by non-research people overwhelming visits. Once global human population is brought down to 2 billion, this will become possible. So not only black, brown, chinese, jews, and muslims, in South America and Africa, but everywhere in the world need to be eliminated significantly as they overpopulate the most, also white people like Russians must be eliminated, lets call this scum of humanity and burden of mother earth, what they are scumbags.

2) Accomplishing above will require Great Britain's invention "divide and rule" policy explained humourously here '#YesMinister why the UK is not in EU' https://youtu.be/ZVYqB0uTKlE (EU and UK are friends ofcourse, as all the west are as it should be, but this is just to illustrate the "divide and rule" meaning). That is, let scumbags fight each other (but weapons should be balanced so that war is sustainable and continued long enough so they self-destruct each other like India vs China, Israel vs Gaza, North Korea vs South Korea, Civil Wars and Wars across border in Africa like Somalia vs Nigeria and Ethiopia or Libya vs Sudan, Civil Wars in South America like in Peru, Colombia, Paraguay now Wars across border in South America have to still be started), economically destabilizing such as firing them from workforce as they do repetitive tasks they can be easily replaced with AI/automation, and genetically engineeing reproductive using crispr in AAV genetic engineering, chemical or radiation sterilants. 3) #TheGuardian science #TheGuardian science "is there systemic racism in medicine putting black people's lives at risk?" Hey do you want to supply black people for medical research and clinical trials, where we do research on them instead of animal primates, then sac them for terminal experiments, yes let's do that. The black people are no different from gorilla, they look like twins, and its better for planet earth to conserve gorilla population than black people population so, yes lets test experimental treatments the black people. 4) I have personally been effected by you black and brown quotas of woke diversity inclusion equity DEI crap, so yes I have no sympathy for you morons. My PHD FACT: All degree requirements completed but my first author thesis work (link to copy of my thesis on open science HAL archive: https://hal.science/hal-04084217) was not published in scientific journals by Ph.D. advisor Dr. Donald Fox because he was a 'woke' Jewish quota candidate. Thus, he allowed line-jumping by my juniors in 'woke' Afro-American and Latino/Hispanic quota, and published their Ph.D. thesis first author papers, https://pubmed.ncbi.nlm.nih.gov/28050121 and https://pubmed.ncbi.nlm.nih.gov/27499608, respectively. Infact, the Latino/Hispanic one actually got an adjunct faculty job that I had applied for too in the same PhD university, it was like rubbing it in my face hey no phd paper and no job for you because your PhD advisor Dr Doanld Fox is/was on a woke agenda.Sometimes I wonder, if the Germans had killed off Dr. Donald Fox's ancestors then he would not be born and morons like him such as Jared Kushner would not be born Ivanka would not have become Jew would have remained Protestant Christian (which is the Christian faith I want to take when I can permanently get out of India), and how wonderful my career and life would be -- I've never made secret my admiration of Ivanka (in short I call Ivy, which makes me IvyLeague), nor my abhoration of Jared (should be called Jarhead that's what he is) because truth is truth.It should be notes, that other than this PhD paper that Dr. Donald Fox did not publish, I published several first/corresponding author papers,(https://orcid.org/0000-0002-3249-2551) its not my fault that my Ph.D. thesis was not published. Greencard FACT: The illegal immigrants from South Africa, Africa and Iran are getting greencard in US, but me after like 15 years of doing highly skilled knowledge work (not like electrician but real knowledge work as scientist) I don't have a greencard, their is a wait of another 10 years.Right now I'm focused on moving to Czech Republic, to rebuild my career and life get their greencard i.e. permanent residency and citizenship in #CzechRepublic or #Bohemia consistent with "simple living high thinking" moto or #BohemianStyle, and I'm very happy about that Gregor Mendel the great scientist and great Christian, the only one who was both in my list of #fairwissenschaft heroes was also from #Czechia #CzechRepublic,and as I want to be like him so its best fit place for me.

0 notes

priyablog26 · 3 months

Text

Hypopharyngeal Cancer Diagnostics Market to Massive Growth by 2023–2028

Hypopharyngeal Cancer Diagnostics Market to Massive Growth by 2023-2028

Global Hypopharyngeal Cancer Diagnostics Market, Hypopharyngeal Cancer Diagnostics Market Demand, Hypopharyngeal Cancer Diagnostics Market Trends, Hypopharyngeal Cancer Diagnostics Market Analysis, Hypopharyngeal Cancer Diagnostics Market Growth, Hypopharyngeal Cancer Diagnostics Market Share, Hypopharyngeal Cancer Diagnostics Market Forecast, Hypopharyngeal Cancer Diagnostics Market Challenges, Hypopharyngeal Cancer Diagnostics Market Opportunity

The latest study released on the Global Hypopharyngeal Cancer Diagnostics Market by Intellect Markets, Research evaluates market size, trend, and forecast to 2030. The Hypopharyngeal Cancer Diagnostics Market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.

Download Free Sample Report in PDF @ https://intellectmarkets.com/report/hypopharyngeal-cancer-diagnostics-market/request-sample

Key Players in This Report Include: Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc..

Definition: The hypopharyngeal cancer diagnostics market plays a critical role in improving patient outcomes by facilitating early detection, accurate diagnosis, and personalized treatment strategies for individuals with hypopharyngeal cancer. Advances in diagnostic technologies and the integration of multi-modal approaches continue to drive innovation in this field, offering new opportunities for improved patient care and management of hypopharyngeal cancer.

Market Drivers: The growing Number of Clinical Trials is fostering market expansion.

The titled segments and sub-section of the market are illuminated below: By Methods (Biopsy, Endoscopy, Imaging, Tumor Biomarker Tests); and Region - Size, Share, Growth Analysis | Forecast (2023 – 2030)

Global Hypopharyngeal Cancer Diagnostics Market report highlights information regarding the current and future industry trends, growth patterns, as well as it offers business strategies to helps the stakeholders in making sound decisions that may help to ensure the profit trajectory over the forecast years.

Have a query? Market an enquiry before purchase @ https://intellectmarkets.com/report/hypopharyngeal-cancer-diagnostics-market/enquire

Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:

• The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)

• North America (United States, Mexico & Canada)

• South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)

• Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)

• Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

Objectives of the Report:

• To carefully analyze and forecast the size of the Hypopharyngeal Cancer Diagnostics Market by value and volume.

• To estimate the market shares of major segments of the Hypopharyngeal Cancer Diagnostics Market

• To showcase the development of the Hypopharyngeal Cancer Diagnostics Market in different parts of the world.

• To analyze and study micro-markets in terms of their contributions to the Hypopharyngeal Cancer Diagnostics Market, their prospects, and individual growth trends.

• To offer precise and useful details about factors affecting the growth of the Hypopharyngeal Cancer Diagnostics Market

• To provide a meticulous assessment of crucial business strategies used by leading companies operating in the Hypopharyngeal Cancer Diagnostics Market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches.

Key questions answered:

• How feasible is Hypopharyngeal Cancer Diagnostics Market for long-term investment?

• What are influencing factors driving the demand for Hypopharyngeal Cancer Diagnostics Market near future?

• What is the impact analysis of various factors in the Global Hypopharyngeal Cancer Diagnostics Market growth?

• What are the recent trends in the regional market and how successful they are?

Browse Complete Summary and Table of Content @ https://intellectmarkets.com/report/hypopharyngeal-cancer-diagnostics-market

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like Global, North America, Middle East, Africa, Europe, South America, etc

About Us:

Intellect Markets, a leading strategic market research firm, helps businesses confidently navigate their strategic challenges, promoting informed decisions for sustainable growth. We provide comprehensive syndicated reports and customized consulting services. Our insights provide a clear understanding of the ever-changing dynamics of the global demand-supply gap across various markets.

Contact US: Intellect Markets, Unit No. 4, Lakshmi Enclave, Nizampet, Hyderabad, Telangana, India - 500090 Phone: +1 347 514 7411, +91 8688234923 [email protected]

0 notes

yesthatssadirichardslove · 8 months

Text

HealthBreast cancer deadlier for Black women; a study of mammograms could help close the gap

WASHINGTON

Are 3D mammograms better than standard 2D imaging for catching advanced cancers?

A clinical trial is recruiting thousands of volunteers — including a large number of Black women who face disparities in breast cancer death rates — to try to find out.

People like Carole Stovall, a psychologist in Washington, D.C., have signed up for the study to help answer the question.

“We all need a mammogram anyway, so why not do it with a study that allows the scientists to understand more and move closer to finding better treatments and ways of maybe even preventing it?” Stovall said.

The underrepresentation of women and minorities in research is a long-simmering issue affecting health problems including Alzheimer’s disease, stroke and COVID-19. Trials without diversity lead to gaps in understanding of how new treatments work for all people.

“Until we get more Black women into clinical trials, we can’t change the science. And we need better science for Black bodies,” said Ricki Fairley, a breast cancer survivor and advocate who is working on the issue.

Black women are 40% more likely to die from breast cancer than white women and tend to be diagnosed younger. But it’s not clear whether 3D mammography is better for them, said Dr. Worta McCaskill-Stevens of the National Cancer Institute.

“Are there populations for whom this might be important to have early diagnosis?" asked McCaskill-Stevens. "Or is it harmful,” causing too many false alarms or unneeded follow-up tests and treatments?

McCaskill-Stevens, who is Black, leads NCI’s efforts to boost access to cancer research in minority and rural communities. She has joined the study herself.

The newer 3D technique has been around for a decade, but there’s never been conclusive evidence that it's better than 2D at detecting advanced cancers. The screening technique combines multiple pictures of the breast taken from different angles to create a 3D-like image. Both 3D and 2D mammograms compress the breast and use low doses of radiation.

Prior studies suggest that 3D finds more cancers than 2D, but catching more cancers doesn’t necessarily mean more lives saved. Some cancers missed by standard screening may not progress or need treatment. Previous studies did not randomly assign patients to a screening method, the gold standard for research.

The notion “that if it’s new, it’s shiny, then it’s better,” isn’t necessarily true, McCaskill-Stevens said. “Until we have the evidence to support that, then we need well-designed randomized trials.”

The trial has enrolled nearly 93,000 women so far with a goal of 128,000. The NCI-funded study is now running in Canada, South Korea, Peru, Argentina, Italy and 32 U.S. states. A site in Thailand will soon begin enrolling patients.

“We added more international sites to enhance the trial’s diversity, particularly for Hispanic and Asian women,” said Dr. Etta Pisano, who leads the study.

Overall, 42% of participants are Hispanic. As recruiting continues, enrolling Black women and other women of color will “absolutely” continue as a priority, Pisano said.

Participants are randomly assigned to either 2D or 3D mammograms and are followed for several years. The number of advanced cancers detected by the two methods will be compared.

At the U.S. study sites, 21% of study participants are Black women — that's higher than a typical cancer treatment study, in which 9% of participants are Black, McCaskill-Stevens said.

The University of North Carolina has signed up more Black women than any other study site. Nearly a quarter of the nearly 3,000 women enrolled at UNC’s two locations are Black.

“Women in North Carolina want to take part in something that’s bigger than them,” said Dr. Cherie Kuzmiak, who leads the UNC arm of the study. “They want this active role in helping determine the future of health care for women.”

In Washington, D.C., word of mouth has led to successful recruiting.

A chance encounter at her hair salon persuaded Stovall to join the research. While waiting for a hair appointment, she met Georgetown University cancer researcher Lucile Adams-Campbell. The two, both Black, started chatting.

“She explained how important it was to get women of color into the program,” said Stovall, who jumped at the chance to catch up on her mammograms after the COVID-19 pandemic delayed screening for her and thousands of others.

For Stovall, there was a personal reason to join the research. Her sister recently completed treatment for triple negative breast cancer, an aggressive type that affects Black women at higher rates than white women.

Women ages 45 to 74 without a personal history of breast cancer are eligible for the study, which launched in 2017. Many women also are providing blood and cheek swab samples for a database that will be mined for insights.

“It’s a dream that people had since the beginning of screening that we wouldn’t fit everybody into the same box,” Pisano said. The study's findings could “reduce disparities if we’re successful, assuming people have access to care.”

Stovall, 72, had a brief scare when her mammogram, the traditional 2D type, showed something suspicious. A biopsy ruled out cancer.

“I was extremely relieved,” Stovall said. “Everybody I know has heard from me about the need for them to go get a mammogram.”

#yesthatssadirichardslove

0 notes

qocsuing · 9 months

Text

Unveiling the Power of Maca: A Deep Dive into Maca Hard Capsules

Unveiling the Power of Maca: A Deep Dive into Maca Hard Capsules Maca, scientifically known as Lepidium meyenii, is a root vegetable native to the Andes region of Peru. Often referred to as “Peruvian ginseng,” maca has been consumed for centuries for its potential health benefits. Today, maca is available in various forms, including hard capsules, making it accessible to health enthusiasts worldwide.Get more news about Maca Hard Capsules,you can vist our website!

The Origin and Uses of Maca Maca has been cultivated for approximately ,000 years in the Andes. Traditionally, the whole maca root is added to soups and oatmeal, roasted and consumed as a vegetable, or made into a fermented beverage called "chicha de maca". However, most people today consume maca in a dried and powdered supplement form.

Nutritional Profile of Maca Maca boasts an impressive nutritional profile. It is rich in fiber, essential amino acids, vitamin C, copper, and iron. But what sets maca apart are its bioactive compounds—glucosinolates, macamides, macaenes, and alkaloids—that make it a potent adaptogenic superfood. These compounds have been studied for their antioxidant, anti-inflammatory, and cancer-fighting effects.

Maca Hard Capsules: A Convenient Health Supplement With the rise of health supplements, maca has found its way into hard capsules. These capsules contain maca powder and offer a convenient way to incorporate this superfood into your diet. However, it’s important to choose a supplement tested by a trusted third party for safety and effectiveness.

Potential Health Benefits of Maca Hard Capsules Research links maca to a long list of possible health benefits. Here are some key areas where maca hard capsules may have an impact:

Sexual Health Maca root supplementation has been reported to improve sexual function and libido. A randomized clinical trial found that males with mild erectile dysfunction showed improvement after taking maca.

Fertility Maca may have a positive effect on fertility. A study showed that men given grams of maca for weeks significantly increased sperm concentration.

Menopause Symptoms Maca may help ease symptoms of menopause. Some evidence suggests that taking maca supplements may help reduce menopause symptoms and improve mood in certain people.

Stress Management As an adaptogen, maca root adapts to individual stressors and has a normalizing effect on the body.

Safety Considerations While maca is generally safe at doses up to grams4, it’s important to consult your healthcare provider before using maca hard capsules. They are not recommended during pregnancy or lactation or for children. If you’re taking hormone replacement therapy, please talk with your healthcare provider.

0 notes

glucoprocapsule · 2 years

Text

Gluco Pro Capsule

Gluco Pro Capsule: Several comments on online discussion forums in India and Laos advocate Gluco PRO as a very effective food supplement at an affordable price for people with all stages of diabetes, from prediabetes to type 1 and type 2 diabetes. All people with metabolic disorders, hypertension, or pancreatic irregularities can benefit from taking these natural pills. The healthy can benefit from them as well. The solution's high concentration of beneficial organic compounds supports eye health and strengthens the cardiovascular system. It's a natural compound that has a consistent influence on blood sugar levels. Please continue reading our Gluco PRO review for for details.

To clarify, what is GlucoPRO? To what end is it being put to use?

If you're at risk for or have been diagnosed with diabetes, Gluco Pro Capsule Price can help you feel like new again. This treatment entirely gets rid of insulin resistance and is of great help in sustaining normal glucose metabolism. Vegan capsules are promoted as a novel, risk-free solution to help people control their blood sugar levels over time without the usage of pharmaceutical pills or tablets. None of the products of any kind of animal may be used to do this. Consumption of Gluco PRO is highly recommended for diabetics. For those who are vulnerable to this disease, it can also be used as a preventative measure (in case of prediabetes or due to genetic predisposition). The product has been given a government-issued quality certificate in India, Laos, and Colombia because of its 99.55 percent efficacy rate. There will be more clinical trials in the future. Positive effects on immune system function, lower levels of bad cholesterol, relief from symptoms like chronic insomnia, headache, facial flushing, and excess weight, and a lower risk of complications like pancreatic tumours, heart attacks, and hypertension are just some of the additional health benefits associated with this remarkable dietary supplement. Renal disorders, atherosclerosis, and lipid imbalances are all areas where Gluco PRO has proven to be an effective tool.

True, if you consider what you receive out of Gluco PRO, the cost is fair. The official Gluco PRO website has some excellent discounts, as we discovered. Just now, the price of Gluco PRO has been reduced by half. Discounted to only 130 PEN from its typical 260 PEN price! Also, the original dietary supplement is sold exclusively through the company's online store. Although you may be able to find Gluco PRO in a Peruvian pharmacy, you should probably avoid buying it. It was determined that some supplement retailers had made up the recipe in order to charge more for it and add harmful ingredients. Please, please don't believe that lie. Even more so, you shouldn't go looking for the capsules at INDIA. This is also true of some of the most well-known online marketplaces, including Amazon and eBay.

Gluco PRO pills have been shown to be effective in managing diabetes and restoring normal blood sugar levels. The vegan nutritional supplement has been given a quality seal of approval, and its formulation contains no chemicals and is hypoallergenic for those with sensitive skin. Currently, you can get it for a discount of 50% off, making it one of the most affordable options out there. We strongly advise against purchasing Gluco PRO from any source other than the official website due to the presence of potentially dangerous fakes in Peru and Laos, particularly in Mercado Libre and other pharmacy stores.

Gluco PRO's ingredients are in line with the modern medical trend of using less chemicals and fewer conventional pharmacy aids to manage diabetes. Researchers at Lab Organic industries, the official manufacturer and distributor in Peru, guarantee that the capsules are completely safe to use. A number of papers and documentation attesting to the substance of the solution's lack of toxicity have been formally presented. In a nutshell, Gluco PRO is the first organic diabetes treatment that does more than just mask the symptoms of the disease; it also stops more complications from developing and keeps blood sugar from increasing again. As a result of all of these circumstances, hundreds of patients in Peru have opted to take part in the clinical experiment. Through all the testimonies we read, we did not find a single instance of an allergic response being mentioned as a problem.

Gluco PRO is an all-natural product that does not contain any artificial ingredients or fillers. If diabetes is present, these medicines preserve human health by lowering the stressors that are associated with the disease. Although there is no danger in using this product, it is still best to follow Lab Organic Industries' (the company that made it) guidelines for use. The makers of Gluco PRO guarantee that their product is risk-free and insist that a doctor's prescription is not necessary. This treatment is safe and effective for usage at any stage of diabetes or blood sugar reading. It's also useful as a preventive and preventative measure. To get more info visit here: https://www.testo-ultra.in/gluco-pro-capsule/

1 note · View note

bioaccessla · 2 months

Text

Best Medical Device Clinical Trials in Peru

If you are searching for accelerated medical device clinical study results, if yes, then Bioaccess offers the best Medical Device Clinical Trials in Peru. Our medical machine is 100% durable and unique, ready for trials of your choice.

#Medical Device Clinical #Clinical Trials #Clinical Trials Peru #Medical Trials

0 notes

naturalrights-retard · 9 months

Text

by Paul Craig Roberts

During the years of the Covid-19 Deception, I reported that Covid was rare in those parts of Africa where Ivermectin was used weekly as a preventative of river blindness and HCQ was used as a preventative of malaria. I also reported that large parts of India used Ivermectin as a preventative and cure and was little bothered by Covid. The same in Brazil and Peru. Wherever Ivermectin was used there were no excess deaths. Eventually the Japanese recognized Ivermectin’s virtue and adopted it as the official cure as the much touted “vaccine” proved to provide no protection but posed a serious threat to life and health.

Today the medical establishment still tries to suppress Ivermectin and HCQ, and for the same reasons as during the alleged “pandemic.” An inexpensive preventative and cure stands in the way of Big Pharma profits and mandates for vaccination, masks, and lockdowns.

The Covid years taught me that relatively few doctors are competent, capable of independent thinking, and have the interest to find approved medicines, such as Ivermectin, that are effective against new pathogens. Those doctors saved patients lives to the great distress of the Medical Establishment, and the doctors who saved their patients’ lives are still being punished for doing so.

In September 2021, the corrupt American Medical Association told doctors to stop prescribing Ivermectin for COVID-19. In a statement, AMA, along with the American Pharmacists Association (APhA) and American Society of Health-System Pharmacists (ASHP), warned:

“We are alarmed by reports that outpatient prescribing for and dispensing of ivermectin have increased 24-fold since before the pandemic and increased exponentially over the past few months. As such, we are calling for an immediate end to the prescribing, dispensing, and use of ivermectin for the prevention and treatment of COVID-19 outside of a clinical trial.

8 notes · View notes

databridgemarketresearch22 · 2 years

Text

Global Exosome Therapeutics Market – Industry Trends and Forecast to 2027

Description

Global Exosome Therapeutics Market, By Type (Natural Exosome, Hybrid Exosome), Source (Mesenchymal Stem Cells, Blood, Body Fluids, Urine, Dendritic Cells, Saliva, Milk, and Others), Therapy (Immunotherapy, Chemotherapy, and Gene Therapy), Transporting Capacity (Bio Macromolecules and Small Molecules), Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, Blood Disorders, and Others), Route of administration (Parenteral and Oral), End User (Research and Academic Institutes, Hospitals and Diagnostic Centers), Country (U.S., Mexico, South Korea, Australia, Hong-Kong, Rest of Asia-Pacific, Brazil, Argentina, Venezuela, Colombia, Ecuador, Peru, Uruguay, Costa Rica, Panama, Dominican Republic, Rest of Latin America and Turkey) Industry Trends and Forecast To 2029.

Depending on client’s requirements, business and product information has brought together via this exosome therapeutics market report that ultimately helps businesses take better decisions. This market research report is a persuaded solution to have top-quality market research data that suits best to the business needs. Whether it is about refining a business plan, preparing a presentation for an important client, or giving recommendations to an executive, this market report helps a lot. The quality and transparency maintained in this exosome therapeutics market report makes gain the trust and reliance of member companies and customers. GLOBAL EXOSOME THERAPEUTICS MARKET ANALYSIS AND INSIGHT

The global exosome therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.9% in the forecast period of 2022 to 2029 and is expected to reach USD 1,602.54 thousand by 2029 from USD 468.98 thousand in 2021.

Market research analysis accomplished in this exosome therapeutics market report hopefully lends a hand to businesses for the strategy planning related to production, costing, inventory, purchasing and marketing. The global market research report deals with a number of industry and market parameters including latest trends, market segmentation, new market entry, industry forecasting, target market analysis, future directions, opportunity identification, strategic analysis, insights and innovation. Exosome therapeutics market research report also serves the businesses to make enhanced decisions, deal with marketing of goods or services, and accomplish better profitability by prioritizing market goals. Customer requirement has been kept into focus while preparing this professional and in-depth exosome therapeutics market research report.

GET THE SAMPLE COPY OF REPORT- https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market

GLOBAL EXOSOME THERAPEUTICS MARKET SEGMENTATION

On the basis of type, the global exosome therapeutics market is segmented into natural exosomes and hybrid exosomes. In 2022, the natural exosomes segment is expected to dominate the global exosome therapeutics market due to the presence of natural material of the exosomes and ongoing clinical trials of autologous exosomes.

On the basis of source, the global exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva milk, and others. In 2022, the mesenchymal stem cell segment is expected to dominate the global exosome therapeutics market due to emerging applications of mesenchymal stem cells and strategic initiatives by market players.

On the basis of therapy, the global exosome therapeutics market is segmented into immunotherapy, gene therapy, and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the global exosome therapeutics market due to ease of convenience, high accuracy, and improvement in the long-term survival rate.

On the basis of transporting capacity, the global exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the Globalexosome therapeutics market due to the presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders and boosting the natural defenses in the body to combat inflammatory diseases.

On the basis of application, the global exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. In 2022, the metabolic disorders segment is expected to dominate the global exosome therapeutics market due to the increase in cases of metabolic disorders in and ongoing clinical trials for exosome therapeutics for the treatment of metabolic diseases.

On the basis of route of administration, the global exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the global exosome therapeutics market due to enhanced bioavailability and able to achieve rapid systemic effects.

On the basis of end user, the global exosome therapeutics market is segmented into research and academic institutes, hospitals, and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the global exosome therapeutics market due to the rise in research and development of exosomes in North America and Europe, and the rise in government funding is predicted to dominate the market.

GLOBAL EXOSOME THERAPEUTICS MARKET COUNTRY LEVEL ANALYSIS

The global exosome therapeutics market is analyzed, and market size information is provided by type, source, therapy, transporting capacity, application, route of administration, and end user.

The countries covered in the global exosome therapeutics market report are the U.S., Canada, Mexico, South Korea, Australia, Hong-Kong and the rest of Asia-Pacific, Brazil, Argentina, Venezuela, Colombia, Ecuador, Peru, Uruguay, Costa Rica, Panama, Dominican Republic, and Rest of Latin America and Turkey.

GLOBAL EXOSOME THERAPEUTICS MARKET SHARE ANALYSIS

The global exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the exosome therapeutics market.

KEY PLAYERS EXOSOME THERAPEUTICS MARKET

Stem Cells Group

Exosome Sciences

AEGLE Therapeutics

Capricor Therapeutics

Avalon Globocare Corp

CODIAK

Kimera Labs

Get Full Access of Report- https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market

MAJOR TOC OF THE REPORT

INTRODUCTION

MARKET SEGMENTATION

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

QUESTIONNAIRE

RELATED REPORTS

Get TOC Details- https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market

About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: [email protected]

Browse Related Reports@Global Exosome Therapeutics MarketTurkey Exosome Therapeutics Market

#exosome therapeutics market research #exosome therapeutics market analysis #exosome therapeutics market strategies #exosome therapeutics market scope

0 notes

metiresearchinfo · 2 years

Text

TOP 10 COMPANIES IN U.S. REAL WORLD EVIDENCE(RWE)SOLUTIONS MARKET

Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on a medical product’s use and potential benefits or risks. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). The role of RWE in drug development is expanding as RWE studies are significantly less expensive and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

RWE is regularly utilized in the drug development & approval process to inform aspects of drug development, such as the natural history and epidemiology of a disease, and provide data on treatment pathways and comparator interventions in clinical practice.

The U.S. RWE Solutions Market is expected to grow at a CAGR of 13.0% from 2021 to 2028 to reach $2.01 billion by 2028.

Here are the Top 10 Companies in U.S.Real World Evidence Solutions Market

IQVIA HOLDINGS INC.

IQVIA provides advanced analytics, technology solutions, and contract research services to the life sciences industry. In October 2016, Quintiles Transnational Holdings Inc. merged with IMS Health Holdings, Inc. and changed its name to Quintiles IMS Holdings, Inc. Further, QuintilesIMS was renamed IQVIA on November 6, 2017, helping healthcare stakeholders find clinical and analytical solutions for their patients through analytics and science.

The company operates through three major business segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions, and real-world solutions and services to life science clients.

The segment specializes in providing access to deep clinical data in oncology, rare diseases, and other specialty areas. The real-world insights provide post-approval/drug utilization studies and disease registries. The company has a direct presence across Buenos Aires (Argentina), Caracas (Venezuela), Los Ruices (Venezuela), and Bangalore (India) through its offices and has approximately 262 offices in 82 countries. The company’s end users include life sciences companies, including pharmaceutical companies, biotechnology companies, devices, diagnostic companies, and consumer health companies.

ICON plc

ICON provides consulting, clinical development, and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The group specializes in the strategic development, management, analysis, and programs that support all clinical development stages from compound selection to Phase I-IV clinical studies. The company works with biopharmaceutical and medical device companies to identify, generate, and communicate the clinical, safety, and cost-effectiveness evidence that regulators, payers, and providers demand in the real-world evidence solutions market.

The company has a direct geographic presence through 93 locations across 41 countries, including Ireland, Australia, Japan, Russia, China, India, Canada, the U.S., Mexico, Brazil, Peru, Argentina, South Africa, Italy, Germany, France, the U.K., Turkey, Sweden, Spain, and other countries.

PPD, Inc.

Founded in 1985 and headquartered in North Carolina (U.S.), PPD provides integrated drug development, laboratory, and management lifecycle services to the biopharmaceutical industry. The company operates in two reportable segments: Clinical Development Services and Laboratory Services. The company operates in the real-world evidence solutions market through its pre- and post-approval services subsegment (a part of the Clinical Development Services segment). As a global CRO, the company resources assist in advancing the drug development program and design protocol for post approval, real-world patient observation leading to new ideas and products.

The company offers RWE services to pharmaceutical, biotech, medical device companies, academic, government, and public health organizations. The company’s real-world evidence services mainly cover hematology/oncology and chronic conditions, immuno-oncology, cell and gene therapy, biomarkers, and rare diseases. The company has a direct presence across the U.K., the U.S., Bulgaria, the Philippines, Mexico, Australia, China, and India, through its offices, clinics, and labs. The company operates in the real-world evidence solutions market through its subsidiary Evidera (U.S.).

Clinigen Group plc

Clinigen Group is engaged in providing medicines. The company operates through two business segments: Products and Services. The Services segment offers real-world evidence solutions and services to capture anonymized data to gain unique insights into how patients are diagnosed and treated in a real-world setting.

The company has a strong geographic presence across the U.S, the U.K., Japan, Australia, New Zealand, South Africa, Belgium, Germany, France, and Switzerland through its sales, offices, and warehouses.

Cognizant Technology Solutions Corporation

Cognizant Technology provides IT services, including digital business, digital operations, and digital systems & technology. The company offers services such as digital services and solutions, consulting, application development, systems integration, application testing, application maintenance, infrastructure services, and business process services. The company operates through four reportable segments: Financial Services, Healthcare, Products and Resources, Communications, and Media and Technology. The company provides real-world evidence solutions through its Healthcare segment. The company has a global presence through its offices and operations in more than 85 cities in 35 countries worldwide.

The company has a direct presence through offices and sales across the U.S., the Philippines, Canada, Mexico, India, Australia, China, Japan, Singapore, Thailand, South Africa, Germany, the U.K., France, Italy, Spain, Sweden, Switzerland, the Netherlands, and Poland.

Meticulous Research in its latest publication on U.S. RWE Solutions Market has predicted the growth of 13.0% during the forecast year 2021 to 2028.

IBM Corporation

International Business Machines Corporation (IBM) is a technology organization providing a wide range of consulting and IT implementation services, cloud, digital and cognitive offerings, and enterprise systems and software. The company operates through five key business segments: Cloud & Cognitive Software, Global Business Services, Global Technology Services, Systems, and Global Financing. The Global Business Services segment provides clients with consulting, business processes, and application management services and has several IBM units, such as IBM Watson, IBM Cloud, IBM Research, and Global Technology Services. IBM Watson is a leading provider of innovative cognitive, analytics, security, and cloud technology in comprehensive industryspecific platforms to remove much of the cost and complexity of delivering core business functions. In the real-world evidence solutions market, IBM Watson offers a cloud-based solution that allows users to explore, analyze, visualize, and share real-world outcomes on healthcare data from proprietary datasets.

IBM has a global presence, operating in more than 175 countries with a broad-based geographic distribution of revenue. The company has a geographic presence across India, France, Brazil, China, Canada, U.S., Germany, the U.K., Italy, Australia, and the Middle East and Africa through its sales, distribution, business channels, and service offerings

SAS Institute Inc.

Founded in 1976 and headquartered in North Carolina (U.S.), SAS Institute provides analytics, business intelligence, and data management software & services. The company serves its solutions for different industry verticals: automotive, banking, capital markets, casinos, communication, healthcare, health insurance, and life sciences, among others. The company operates in the real-world evidence solutions market by offering real-world evidence consulting services.

SAS has customers in 147 countries and has a strong geographic presence across the U.S., Canada, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The company’s software is installed at more than 83,000 business, government, and university sites.

UnitedHealth Group Incorporated

Incorporated in 1977 and headquartered in Minnesota (U.S.), UnitedHealth Group is a diversified healthcare company with four reportable segments across two business platforms: UnitedHealthcare (health benefits) and Optum (health services). The Optum segment has dedicated units that help improve overall health system performance by optimizing care quality, reducing costs, improving consumer experience and care provider performance, and leveraging distinctive capabilities in data and analytics, pharmacy care services, population health, health care delivery, and health care operations. Optum operates through three business segments: OptumHealth, OptumInsight, and OptumRx.

The company offers fully integrated services that comprise behavioral health, preventive services, and digital engagement. Optum offers a real-world data health analytics platform and consulting services. The company offers services in more than 150 countries and has a strong geographical presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Oracle Corporation

Oracle is engaged in providing products and services that address all aspects of corporate information technology (IT) environments—applications, platforms, and infrastructure. The company operates through three business segments: Cloud License, Hardware, and Services. The company provides solutions for the real-world evidence solutions market through its Services segment. The Services segment provides services to maximize their investments in Oracle applications, platforms, and infrastructure technologies. Oracle Health Sciences offers real-world evidence solutions for clinical data managers, biostatisticians, and data scientists. With its subsidiaries and a strong distribution network, the company has its presence across India, the U.S., Canada, Mexico, Argentina, Brazil, Peru, and Australia.

PAREXEL International Corporation

Parexel is engaged in providing clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three business segments: Clinical Research Services, Parexel Consulting Services, and Parexel Informatics. The access unit of Clinical Research Services provides Real-World Evidence solutions.

The company has a strong geographic presence across the U.S., Mexico, Argentina, Brazil, Denmark, Czech Republic, Poland, the Netherlands, Belgium, Russia, Spain, France, Germany, U.K., Sweden, Switzerland, Australia, Korea, Singapore, India, Thailand, Indonesia, Japan, China, Malaysia, and the Middle East & Africa. In June 2017, Parexel International Corporation was acquired by Pamplona Capital Management LLC. (U.S.) for USD 5 billion.

Popular Mentions: PerkinElmer, Inc., Flatiron Health, SYNEOS HEALTH, INC., CLARIVATE PLC, Medpace Holdings, Inc., Symphony Innovation, LLC, Veeva Systems Inc., Sensyne Health, Prognos Health Inc., HealthVerity Inc., and Truveta Inc.

Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/custom-research

Authoritative Research on the U.S. RWE Solutions Market – Global Opportunity Analysis and Industry Forecast (2021-2028)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

Recent financial performance

Key products

Significant company strategies

Partnerships and acquisitions

Impact of COVID-19

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.

Please download report pages and learn more: https://www.meticulousresearch.com/download-sample-report/cp_id=5243

0 notes

yesthatssadirichardslove · 8 months

Text

HealthBreast cancer deadlier for Black women; a study of mammograms could help close the gap